Physician profile
Arthur Molina
NPI 1699718007
$1,546.68
in general payments reported to CMS, 2019-2025
27 companies · $1,056 in 2025
The $1,056 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.85 · 2021: $35.85 · 2022: $77.99 · 2024: $363 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340 · Education: $79.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.84 |
| Education | $79.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $209.48 | 2024-2025 | |
| Glaxosmithkline, LLC. | $146.07 | 2025 | Zejula, Jemperli, Ojjaara |
| Genzyme Corporation | $140.92 | 2025 | |
| Pfizer INC. | $130.49 | 2025 | |
| Array Biopharma INC | $78.62 | 2024-2025 | Braftovi, Lorbrena, Xalkori |
| Sanofi-Aventis U.S. LLC | $77.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $77.45 | 2025 | Imfinzi, Enhertu |
| Genentech USA, INC. | $73.45 | 2025 | Venclexta |
| Gilead Sciences, INC. | $68.66 | 2021-2025 | Trodelvy |
| Eisai INC. | $65.96 | 2025 | |
| Daiichi Sankyo INC. | $52.51 | 2024-2025 | Injectafer |
| Abbvie INC. | $51.03 | 2025 | |
| Merck Sharp & Dohme LLC | $46.58 | 2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $42.73 | 2024-2025 | Opdualag, Opdivo |
| Emd Serono, INC. | $33.36 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $25.34 | 2025 | Brukinsa |
| Astellas Pharma US INC | $24.91 | 2025 | Cresemba |
| Acrotech Biopharma INC. | $24.68 | 2024 | Beleodaq |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Exelixis INC. | $23.54 | 2025 | Cabometyx |
| Celgene Corporation | $23.23 | 2025 | Reblozyl |
| Mirati Therapeutics, INC. | $22.51 | 2024 | Krazati |
| Secura Bio, INC. | $19.51 | 2025 | Copiktra |
| Janssen Biotech, INC. | $16.80 | 2024 | Talvey, Darzalex, Tecvayli |
| Alnylam Pharmaceuticals INC. | $16.59 | 2024 | Oxlumo |
| Fennec Pharmaceuticals, INC. | $16.49 | 2024 | Pedmark |
| Omeros Corporation | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Molina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.